{"disease":{"id":"neuroendocrine-carcinomas","name":"neuroendocrine carcinomas"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06683846","title":"Ivonescimab in the Treatment of Multiple Advanced Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07192991","title":"Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Latin American Cooperative Oncology Group","has_results":false},{"nct_id":"NCT02820857","title":"Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT05337735","title":"A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":140,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06041516","title":"A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05714722","title":"Epiction of the Genomic and Genetic Landscape Identifies CCL5 as a Protective Factor in Colorectal Neuroendocrine Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT06893783","title":"Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Inkeun Park","has_results":false},{"nct_id":"NCT05126433","title":"Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":47,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":true},{"nct_id":"NCT07014540","title":"A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT04525638","title":"A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Fundación de investigación HM","has_results":false},{"nct_id":"NCT04122911","title":"Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"National Cancer Institute, Naples","has_results":false},{"nct_id":"NCT02457273","title":"Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"National Health Research Institutes, Taiwan","has_results":false},{"nct_id":"NCT03042780","title":"FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}